ME01442B - Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjena - Google Patents
Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjenaInfo
- Publication number
- ME01442B ME01442B MEP-2010-207A MEP20710A ME01442B ME 01442 B ME01442 B ME 01442B ME P20710 A MEP20710 A ME P20710A ME 01442 B ME01442 B ME 01442B
- Authority
- ME
- Montenegro
- Prior art keywords
- tablet formulation
- pramipexole
- pharmaceutically acceptable
- acceptable salt
- polymer
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title claims 10
- 229960003089 pramipexole Drugs 0.000 title claims 10
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims 10
- 150000003839 salts Chemical class 0.000 title claims 10
- 239000007916 tablet composition Substances 0.000 title claims 10
- 238000000034 method Methods 0.000 title claims 6
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 14
- 229920000642 polymer Polymers 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000003826 tablet Substances 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 6
- 238000000227 grinding Methods 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- 239000007939 sustained release tablet Substances 0.000 claims 5
- 229920006318 anionic polymer Polymers 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 238000007906 compression Methods 0.000 claims 3
- 230000006835 compression Effects 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 229920000881 Modified starch Polymers 0.000 claims 2
- 238000007908 dry granulation Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 238000005056 compaction Methods 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003130 hypromellose 2208 Polymers 0.000 claims 1
- 229940031707 hypromellose 2208 Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1.Tabletna formulacija sa produženim otpuštanjem obuhvata pramipeksol ili njegovu farmaceutski prihvatljivu so u matriksu koji sadrži bar dva polimera koji bubre u vodi, osim preželatinizovanog škroba, i pri čemu bar jedan od dva polimera je anjonski polimer
2.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 1, pri čemu je anjonski polimer odabran iz grupe od opciono unakrsno povezanih polimera akrilne kiseline, polimera metakrilne kisleine, alginata i karboskimetil celuloze.
3.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 2, pri čemu je anjonski polimer opciono unakrsno povezani polimer akrilne kiseline, i pri čemu je sadržaj opciono unakrsno povezanog polimera akrilne kiseline u matriksu od oko 0.25 tež.-% do oko 25 tež.-%, a prvenstveno od oko 0.5 tež.-% do oko 15 tež.-%, a naročito od oko 1 tež. -% do oko 10 tež.-%.
4.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 1, pri čemu je bar jedan od dva polimera jako neutralni polimer, osim preželatinizovanog škroba.
5.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 4, pri čemu je jako neutralni polimer odabran od hidroksipropilceluloze i hidroksipropilmetilceluloze.
6.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 4, pri čemu je jako neutralni polimer hidroksipropil metilceluloza, i pri čemu je sadržaj hidroksipropil metilceluloze u matriksu od oko 10 tež.-% do oko 75 tež.-%, a prvenstveno od oko 25 tež.-% do oko 65 tež.-%.
7.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 4, pri čemu matriks sadrži oko: (a)pramipeksola ili njegovu so 0.05 do 5 tež.-% (b)anjonski polimer(e) koji bubri(e) u vodi 0.25 do 25 tež.-% (c)neutralni polimer(e) koji bubri(e) u vodi 10 do 75 tež.-% (d)druge ekscipijente do 100 tež.-%
8.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 1, se sastoji od Pramipeksol-dihidrohlorid monohidrata, Hipromeloze 2208, Kukuruznog škroba, Karbomera 941, Koloidnog silicijum dioksida i Magnezijum stearata.
9.Tabletna formulacija sa produženim otpuštanjem prema zahtevu 1, rezultujuća tableta koja predviđa otpuštajuću osobinu koje je zavisna od pH sa bržom otpuštajućom osobinom u opsegu od pH < 4.5, a sporijom i dodatno otpuštajućom osobinom koja je nezavisna od pH u opsegu od pH 4.5 do 7.5.
10.Tabletna formulacija sa produženim otpuštanjem prema bilo kojem od prethodnih zahteva, pri čemu je količina sadržajnog pramipeksola ili njegove farmaceutski prihvatljive soli dovoljna da obezbedi dnevnu dozu primene u jedno vreme.
11.Postupak proizvodnje tabletne formulacije sa produženim otpuštanjem prema jednom od zahteva 1 do 10, putem postupka direktne kompresije koji obuhvata korake (1)proizvodnje aktivne komponente pretvaranjem u prašak, gde je aktivna komponenta pramipeksol ili njegova farmaceutski prihvatljiva so. predmelevenjem sa porcijom polimera koji bubri(e) u vodi i/ili ekscipijenta(ata) u mešalici, gde se pramipeksol ili njegova farmaceutski prihvatljiva so melje, poželjno klinastim mlevenjem, pre primene; (2)predmešanja aktivne komponente pretvorene u prašak u koraku (1), glavne porcije polimera koji bubri(e) u vodi i/ili ekscipijenta(ata) u mešalici kako bi se dobila pred-smeša, (3)opciono suvog granulisanja pred-smeše kroz granulat u cilju da se odvoje kohezione čestice i da se poboljša jednoličnost sadržaja (4)mešanja pred-smeše iz koraka (2) ili (3) u mešalici, opciono dodavanjem preostalih ekscipijenata smeši i kontinualno mešanje, i (5)tabletiranja finalne smeše kompresijom na pogodnoj tabletnoj presi kako bi se dobio matriks tableta.
12.Postupak proizvodnje tabletne formulacije sa produženim otpuštanjem prema jednom od zahteva 1 do 10, putem postupka vlažne granulacije koji obuhvata korake (1)proizvodnje aktivne komponente pretvaranjem u prašak, gde je aktivna komponenta pramipeksol ili njegova farmaceutski prihvatljiva so, mlevenjem sa porcijom ekscipijenata u mešalici, gde se pramipeksol ili njegova farmaceutski prihvatljiva so melje, poželjno klinastim mlevenjem, pre primene; (2)granulisanja aktivne komponente pretvorene u prašak u koraku (1) dodavanjem granulacione tečnosti, prvenstveno vode; (3)sušenja granulata iz koraka (2) u fluidnom slojnom sušaču ili rerni; (4)mešanja osušenog granulata iz koraka (3) sa polimerom(ima) koji bubri(e) u vodi i/ili ekscipijentima u mešalici kako bi se dobila finalna smeša; (5)tabletiranje finalne smeše iz koraka (4) kompresovanjem na pogodnoj tabletnoj presi kako bi se dobili metriksi tableta.
13.Postupak proizvodnje tabletne formulacije sa produženim otpuštanjem prema jednom od zahteva 1 do 10, putem postupka suve granulacije koji obuhvata korake (1)mešanja aktivne komponente pramipeksola ili njegove farmaceutski prihvatljive soli ili sa porcijom punioca ili svim ekscipijentima u mešalici, pri čemu je premipeksol ili njegova farmaceutski prihvatljiva so samljevena, prvenstveno klinastim mlevenjem, pre primene; (2)kompakcije smeše iz koraka (1) na pogodnom cilindričnom kompaktoru; (3)redukcije traka dobijene u koraku (1) na male granule pogodnim mlevenjem ili korakom prosejavanja; (4)opcionog mešanja granula iz koraka (3) sa preostalim ekscipijentima u mešalici kako bi se dobila finalna smeša; (5)tabletiranja granula iz koraka (3) ili finalne smeše iz koraka (4) kompresovanjem na pogodnoj tabletnoj presi kako bi se proizveli matriksi tableta.
14.Primena tabletne formulacije sa produženim otpuštanjem prema jednom od prethodnih zahteva 1 do 10 za dobijanje medicinske kompozicije za lečenje Parkinsonove bolesti i komplikacija ili poremećaja koji su povezani sa tim.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04019248 | 2004-08-13 | ||
| PCT/EP2005/053602 WO2006015942A1 (en) | 2004-08-13 | 2005-07-25 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| EP05777774.0A EP1781260B2 (en) | 2004-08-13 | 2005-07-25 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01442B true ME01442B (me) | 2013-12-20 |
Family
ID=34926161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-195A ME01316B (me) | 2004-08-13 | 2005-07-25 | Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so |
| MEP-2010-207A ME01442B (me) | 2004-08-13 | 2005-07-25 | Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjena |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-195A ME01316B (me) | 2004-08-13 | 2005-07-25 | Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US20060051417A1 (me) |
| EP (6) | EP2286801A3 (me) |
| JP (5) | JP4757872B2 (me) |
| KR (2) | KR101052436B1 (me) |
| CN (4) | CN101005831B (me) |
| AR (1) | AR050602A1 (me) |
| AT (2) | ATE486588T1 (me) |
| AU (3) | AU2005271194B2 (me) |
| BR (2) | BRPI0513846A (me) |
| CA (3) | CA2572864C (me) |
| CY (2) | CY1111713T1 (me) |
| DE (1) | DE602005024570D1 (me) |
| DK (2) | DK1789021T4 (me) |
| EA (4) | EA015335B1 (me) |
| EC (2) | ECSP077242A (me) |
| ES (2) | ES2355735T5 (me) |
| HR (2) | HRP20120068T4 (me) |
| IL (3) | IL181283A (me) |
| ME (2) | ME01316B (me) |
| MX (2) | MX2007001765A (me) |
| NO (2) | NO342453B1 (me) |
| NZ (3) | NZ553587A (me) |
| PH (1) | PH12012501282A1 (me) |
| PL (2) | PL1789021T3 (me) |
| PT (2) | PT1781260E (me) |
| RS (2) | RS51527B2 (me) |
| SG (1) | SG148996A1 (me) |
| SI (2) | SI1781260T2 (me) |
| TW (2) | TWI347850B (me) |
| UA (3) | UA93608C2 (me) |
| WO (2) | WO2006015942A1 (me) |
| ZA (2) | ZA200700085B (me) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| PA8578501A1 (es) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| CN101022788B (zh) * | 2004-08-13 | 2010-11-10 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
| UA93608C2 (ru) * | 2004-08-13 | 2011-02-25 | Берингер Ингельхайм Интернациональ Гмбх | композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ |
| ES2342090T3 (es) * | 2004-08-25 | 2010-07-01 | Essentialis, Inc. | Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos. |
| WO2007056125A2 (en) * | 2005-11-04 | 2007-05-18 | Eastman Chemical Company | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances |
| EP1988875A2 (en) * | 2006-02-10 | 2008-11-12 | Boehringer Ingelheim International GmbH | Modified release formulation |
| WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| FR2900823B1 (fr) * | 2006-05-15 | 2009-02-13 | Bioprojet Soc Civ Ile | Nouvelle forme d'administration du racecadotril. |
| ATE537826T1 (de) | 2006-05-16 | 2012-01-15 | Knopp Neurosciences Inc | Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung |
| WO2008009664A2 (en) * | 2006-07-19 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Treatment of pain |
| US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
| RU2009110253A (ru) * | 2006-08-24 | 2010-09-27 | БЁРИНГЕР ИНГЕЛЬХАЙМ ФАРМА ГМБХ УНД Ко. КГ (DE) | Способ приготовления таблеток прамипексолдигидрохлорида, обладающих высокой стабильностью при хранении |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| JP2010521496A (ja) | 2007-03-14 | 2010-06-24 | ノップ ニューロサイエンシーズ、インク． | キラル精製置換ベンゾチアゾールジアミンの合成 |
| US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
| US20100092554A1 (en) * | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| EP2291178A4 (en) * | 2008-06-09 | 2013-07-24 | Supernus Pharmaceuticals Inc | PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE |
| US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| EP2448411A4 (en) * | 2009-07-02 | 2012-11-28 | Supernus Pharmaceuticals Inc | METHOD OF TREATING A NEUROLOGICAL DISORDER |
| EP2525786A2 (en) * | 2010-01-18 | 2012-11-28 | Synthon BV | Pramipexole extended release tablets |
| US20120059013A1 (en) * | 2010-03-09 | 2012-03-08 | Boehringer Ingelheim International Gmbh | Method of treating early morning akinesia in subjects having parkinson's disease |
| TR201001862A1 (tr) * | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
| KR101406265B1 (ko) * | 2010-03-17 | 2014-06-12 | 영진약품공업주식회사 | 안정성이 개선된 프라미펙솔을 함유하는 약제학적 조성물 및 이의 제조방법 |
| WO2011128914A2 (en) | 2010-04-15 | 2011-10-20 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
| EP2380560A1 (de) | 2010-04-22 | 2011-10-26 | ratiopharm GmbH | Pramipexol enthaltende Matrixtablette |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| JP2013526601A (ja) | 2010-05-24 | 2013-06-24 | ルピン・リミテッド | プラミペキソールの徐放性製剤 |
| WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
| KR101439635B1 (ko) * | 2011-11-01 | 2014-09-11 | 대원제약주식회사 | 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법 |
| CN102406626B (zh) * | 2011-12-02 | 2013-08-28 | 深圳海王药业有限公司 | 盐酸普拉克索缓释片剂及其制备方法 |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| AU2013213317B2 (en) * | 2012-01-23 | 2016-06-30 | Sun Pharmaceutical Industries Limited | In-situ multilayered tablet technology |
| CN102836137A (zh) * | 2012-09-21 | 2012-12-26 | 山东齐都药业有限公司 | 一种高含量均匀度的盐酸普拉克索缓释片剂及其制备方法 |
| EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
| CN103435571B (zh) * | 2012-11-22 | 2015-12-09 | 北京三泉医药技术有限公司 | 四氢苯并噻唑衍生物及其制备方法 |
| CN102988319B (zh) * | 2012-12-10 | 2014-10-08 | 成都欣捷高新技术开发有限公司 | 一种ⅲ晶型盐酸普拉克索片剂及其制备方法 |
| CN103040781B (zh) * | 2013-01-04 | 2014-07-16 | 杭州朱养心药业有限公司 | 盐酸普拉克索片剂药物组合物及其制备方法 |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| CN104161735A (zh) * | 2013-05-19 | 2014-11-26 | 成都康弘药业集团股份有限公司 | 一种含有盐酸普拉克索的缓释制剂及其制备方法 |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| PL3019167T3 (pl) | 2013-07-12 | 2021-06-14 | Knopp Biosciences Llc | Leczenie podwyższonych poziomów eozynofili i/lub bazofili |
| EP3038467B1 (en) | 2013-08-13 | 2020-07-29 | Knopp Biosciences LLC | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
| DK3033081T3 (da) | 2013-08-13 | 2021-05-31 | Knopp Biosciences Llc | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria |
| CN103520128B (zh) * | 2013-10-12 | 2018-08-21 | 石家庄杏林锐步医药科技股份有限公司 | 一种普拉克索的缓释片剂、制备方法及其用途 |
| CN105456216B (zh) * | 2014-08-18 | 2019-11-05 | 江苏神龙药业股份有限公司 | 盐酸普拉克索缓释片剂组合物及其制备方法 |
| JP2016113441A (ja) * | 2014-10-27 | 2016-06-23 | 大原薬品工業株式会社 | プラミペキソール二塩酸塩一水和物を含む放出が延長された錠剤 |
| CN105796519A (zh) * | 2014-12-30 | 2016-07-27 | 浙江京新药业股份有限公司 | 盐酸普拉克索缓释片及其制备方法 |
| CN104606162B (zh) * | 2015-01-07 | 2017-03-29 | 海南康虹医药科技开发有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
| JP6366547B2 (ja) * | 2015-08-03 | 2018-08-01 | 大原薬品工業株式会社 | 光安定性が向上した、プラミペキソール製剤包装体 |
| CN105380917B (zh) * | 2015-08-24 | 2019-01-15 | 江苏神华药业有限公司 | 一种盐酸普拉克索缓释片及其制备方法 |
| CN106983729B (zh) * | 2016-01-21 | 2021-02-26 | 北京北大维信生物科技有限公司 | 普拉克索缓释片及制备方法 |
| CN107951853B (zh) * | 2016-10-17 | 2022-04-08 | 海思科制药(眉山)有限公司 | 一种盐酸普拉克索缓释药物组合物及其制备方法 |
| CN108785263B (zh) * | 2017-04-26 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | 普拉克索或其药用盐的固体药物组合物及其制备方法 |
| CA3049952A1 (en) | 2017-07-26 | 2019-01-31 | Tgx Soft Chew, Llc | Starch-free soft chew for veterinary applications |
| US11234961B2 (en) | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
| CN114939112B (zh) * | 2017-12-28 | 2024-03-01 | 北京北大维信生物科技有限公司 | 普拉克索缓释药物组合物、其制备方法及用途 |
| CN108159007B (zh) * | 2017-12-29 | 2021-04-16 | 成都百裕制药股份有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
| WO2019207606A1 (en) * | 2018-04-27 | 2019-10-31 | Rubicon Research Private Limited | Extended release compositions and process for preparation |
| CN112704668B (zh) * | 2021-01-12 | 2022-09-30 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸普拉克索缓释组合物 |
| CN112716908A (zh) * | 2021-02-03 | 2021-04-30 | 上海雅本化学有限公司 | 一种普拉克索的制备工艺 |
| CN113876729B (zh) * | 2021-11-11 | 2023-05-30 | 南通联亚药业股份有限公司 | 一种盐酸普拉克索缓释片剂及其制备方法 |
| CN114869854A (zh) * | 2022-04-18 | 2022-08-09 | 华裕(无锡)制药有限公司 | 一种生物等效性高的盐酸普拉克索缓释片及其制备方法 |
| CN116637079B (zh) * | 2023-06-21 | 2026-01-06 | 浙江花园药业有限公司 | 一种左氧氟沙星片及其制备方法 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2887440A (en) | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| NL128902C (me) * | 1960-06-06 | |||
| US3458622A (en) | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | Ｌ− アスコルビンサンセイザイノ セイゾウホウ |
| US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| CH649215A5 (de) | 1981-04-29 | 1985-05-15 | Hoffmann La Roche | Pharmazeutische praeparate. |
| SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
| US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
| US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US4666612A (en) * | 1986-03-17 | 1987-05-19 | Kerr-Mcgee Chemical Corporation | Method for recovering a wood preservative from waste sludges |
| US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
| US4709712A (en) * | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
| US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4789549A (en) * | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
| US4859470A (en) | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
| GB8828020D0 (en) * | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| KR0167346B1 (ko) | 1989-06-09 | 1999-01-15 | 로버트 에이. 아미테이지 | 중추신경계 활성을 갖는 헤테로사이클릭 아민 |
| FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| JPH04234812A (ja) | 1990-03-16 | 1992-08-24 | Yamanouchi Pharmaceut Co Ltd | 持続性製剤用顆粒 |
| GB9015822D0 (en) * | 1990-07-18 | 1990-09-05 | Beecham Group Plc | Compositions |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5656296A (en) | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
| US5731338A (en) | 1992-07-02 | 1998-03-24 | Oramed, Inc. | Controlled release pilocarpine delivery system |
| SK281042B6 (sk) | 1992-09-18 | 2000-11-07 | Yamanouchi Pharmaceutical Co., Ltd | Prípravok hydrogélového typu s ustáleným uvoľňovaním |
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| JPH1017497A (ja) * | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
| GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| CA2290966C (en) | 1997-07-01 | 2005-12-20 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
| PT1009387E (pt) | 1997-07-02 | 2006-08-31 | Euro Celtique Sa | Formulacoes estabilizadas de libertacao controlada de tramadol |
| US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
| CA2211778A1 (en) | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| AU756693B2 (en) | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| US6197339B1 (en) | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
| JP2002506031A (ja) | 1998-03-11 | 2002-02-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 組成物 |
| KR20060056417A (ko) | 1998-05-15 | 2006-05-24 | 파마시아 앤드 업존 캄파니 엘엘씨 | 프라미펙솔의 신규 용도 |
| GB9812426D0 (en) | 1998-06-10 | 1998-08-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
| US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| TW407058B (en) | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
| US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
| DE19906290A1 (de) | 1999-02-15 | 2000-08-17 | Falk Pharma Gmbh | Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs |
| MY121142A (en) * | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| EP1169024B1 (en) | 1999-03-31 | 2005-12-21 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| DE60022692T2 (de) | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| EP1261340B1 (en) * | 1999-07-13 | 2009-05-13 | Alpha Research Group, LLC | Compositions and methods for the treatment of parkinson's disease |
| AP2002002410A0 (en) | 1999-08-04 | 2002-03-31 | Ranbaxy Laboratories Ltd | Hydrodynamically Balancing Oral Drug Delivery System |
| CO5210862A1 (es) | 1999-09-15 | 2002-10-30 | Alza Corp | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia |
| GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
| CA2384840A1 (en) | 1999-09-30 | 2001-04-05 | The General Hospital Corporation | Use of pramipexole as a treatment for cocaine craving |
| JP2003512311A (ja) * | 1999-10-19 | 2003-04-02 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | Ｃｎｓ介在性障害を治療するための持続放出製剤 |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CN1434713A (zh) | 1999-12-22 | 2003-08-06 | 法马西亚公司 | 环加氧酶－2抑制剂的缓释制剂 |
| US6467637B2 (en) | 2000-01-27 | 2002-10-22 | The York Group, Inc. | Death care merchandising system |
| PE20011074A1 (es) * | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
| PT1257277E (pt) | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| US6372252B1 (en) * | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| WO2002011727A1 (en) * | 2000-08-08 | 2002-02-14 | Teva Pharmaceutical Industries Ltd. | Stable pergolide mesylate and process for making same |
| ES2187249B1 (es) | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
| SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| US20030032661A1 (en) * | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
| DE10138275A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| CA2470636A1 (en) | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
| CN1638732A (zh) * | 2002-03-04 | 2005-07-13 | 研究及应用科学协会股份有限公司 | 含载体肽的缓释药物制剂 |
| EP1492505B1 (en) | 2002-04-05 | 2015-06-03 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
| EA007156B1 (ru) * | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Замедленно высвобождающие лекарственные композиции гвайфенезина |
| US20030215498A1 (en) * | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
| AU2003247515A1 (en) * | 2002-06-10 | 2003-12-22 | Wyeth | Novel formate salt of o-desmethyl-venlafaxine |
| US20060153908A1 (en) | 2002-06-27 | 2006-07-13 | Brian Strong | Spherical pellet formulations |
| JP4478413B2 (ja) * | 2002-07-11 | 2010-06-09 | 武田薬品工業株式会社 | 被覆製剤の製造法 |
| FR2842734A1 (fr) * | 2002-07-24 | 2004-01-30 | Ethypharm Sa | Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale et compositions pharmaceutiques a administration orale |
| PA8578501A1 (es) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| US20070196481A1 (en) | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
| US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| BR0312876A (pt) * | 2002-07-25 | 2005-06-28 | Pharmacia Corp | Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água |
| US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| WO2004080440A1 (en) * | 2003-03-11 | 2004-09-23 | Korea United Pharm, Inc. | Process for the preparing of hardcapsule formulation containing lansoprazole |
| MXPA05010636A (es) | 2003-04-04 | 2005-12-12 | Pharmacia Corp | Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada. |
| US20050020589A1 (en) | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
| CN101022788B (zh) | 2004-08-13 | 2010-11-10 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
| UA93608C2 (ru) | 2004-08-13 | 2011-02-25 | Берингер Ингельхайм Интернациональ Гмбх | композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ |
| WO2006046256A1 (en) | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
| CA2613631A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| WO2007002518A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
| ATE444750T1 (de) | 2005-08-15 | 2009-10-15 | Univ Virginia | Neurorestauration mit r(+) pramipexol |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| EP1988875A2 (en) | 2006-02-10 | 2008-11-12 | Boehringer Ingelheim International GmbH | Modified release formulation |
| WO2007090883A1 (en) | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| WO2007090882A2 (en) | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
| EP1886665A1 (en) | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| KR20090045945A (ko) * | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 제어 방출 시스템 및 이의 제조방법 |
-
2005
- 2005-07-25 UA UAA200907974A patent/UA93608C2/ru unknown
- 2005-07-25 EP EP10180948A patent/EP2286801A3/en not_active Withdrawn
- 2005-07-25 BR BRPI0513846-9A patent/BRPI0513846A/pt not_active IP Right Cessation
- 2005-07-25 ME MEP-2011-195A patent/ME01316B/me unknown
- 2005-07-25 RS RS20100557A patent/RS51527B2/sr unknown
- 2005-07-25 CN CN200580027635XA patent/CN101005831B/zh not_active Expired - Fee Related
- 2005-07-25 JP JP2007525278A patent/JP4757872B2/ja not_active Expired - Lifetime
- 2005-07-25 CA CA2572864A patent/CA2572864C/en not_active Expired - Fee Related
- 2005-07-25 EA EA200700201A patent/EA015335B1/ru not_active IP Right Cessation
- 2005-07-25 WO PCT/EP2005/053602 patent/WO2006015942A1/en not_active Ceased
- 2005-07-25 SI SI200531200T patent/SI1781260T2/sl unknown
- 2005-07-25 PH PH1/2012/501282A patent/PH12012501282A1/en unknown
- 2005-07-25 HR HRP20120068TT patent/HRP20120068T4/hr unknown
- 2005-07-25 SG SG200808988-0A patent/SG148996A1/en unknown
- 2005-07-25 DE DE602005024570T patent/DE602005024570D1/de not_active Expired - Lifetime
- 2005-07-25 AU AU2005271194A patent/AU2005271194B2/en not_active Ceased
- 2005-07-25 AU AU2005271192A patent/AU2005271192B2/en not_active Expired
- 2005-07-25 CN CN201010198642A patent/CN101849921A/zh active Pending
- 2005-07-25 PT PT05777774T patent/PT1781260E/pt unknown
- 2005-07-25 WO PCT/EP2005/053610 patent/WO2006015944A2/en not_active Ceased
- 2005-07-25 HR HRP20100682TT patent/HRP20100682T4/hr unknown
- 2005-07-25 EP EP05777774.0A patent/EP1781260B2/en not_active Expired - Lifetime
- 2005-07-25 MX MX2007001765A patent/MX2007001765A/es active IP Right Grant
- 2005-07-25 KR KR1020077005700A patent/KR101052436B1/ko not_active Expired - Lifetime
- 2005-07-25 UA UAA200702474A patent/UA89052C2/ru unknown
- 2005-07-25 DK DK05763065.9T patent/DK1789021T4/da active
- 2005-07-25 EP EP09166415A patent/EP2135602A1/en not_active Withdrawn
- 2005-07-25 PL PL05763065T patent/PL1789021T3/pl unknown
- 2005-07-25 ME MEP-2010-207A patent/ME01442B/me unknown
- 2005-07-25 JP JP2007525280A patent/JP4785847B2/ja not_active Expired - Fee Related
- 2005-07-25 ES ES05777774.0T patent/ES2355735T5/es not_active Expired - Lifetime
- 2005-07-25 AT AT05777774T patent/ATE486588T1/de active
- 2005-07-25 CN CN2005800276345A patent/CN101005830B/zh not_active Expired - Lifetime
- 2005-07-25 ES ES05763065T patent/ES2377214T3/es not_active Expired - Lifetime
- 2005-07-25 DK DK05777774.0T patent/DK1781260T4/da active
- 2005-07-25 EP EP11159740A patent/EP2368545A1/en not_active Withdrawn
- 2005-07-25 BR BRPI0513847-7A patent/BRPI0513847A/pt not_active Application Discontinuation
- 2005-07-25 SI SI200531446T patent/SI1789021T1/sl unknown
- 2005-07-25 PL PL05777774T patent/PL1781260T5/pl unknown
- 2005-07-25 EA EA200900930A patent/EA200900930A1/ru unknown
- 2005-07-25 PT PT05763065T patent/PT1789021E/pt unknown
- 2005-07-25 CA CA2736965A patent/CA2736965C/en not_active Expired - Lifetime
- 2005-07-25 CA CA2572729A patent/CA2572729C/en not_active Expired - Lifetime
- 2005-07-25 KR KR1020077005863A patent/KR101406767B1/ko not_active Expired - Fee Related
- 2005-07-25 EP EP11159737A patent/EP2345407A1/en not_active Withdrawn
- 2005-07-25 EA EA200700132A patent/EA016850B1/ru not_active IP Right Cessation
- 2005-07-25 UA UAA200702472A patent/UA86831C2/uk unknown
- 2005-07-25 NZ NZ553587A patent/NZ553587A/en not_active IP Right Cessation
- 2005-07-25 EA EA201001083A patent/EA201001083A1/ru unknown
- 2005-07-25 NZ NZ553561A patent/NZ553561A/en not_active IP Right Cessation
- 2005-07-25 NZ NZ589267A patent/NZ589267A/en not_active IP Right Cessation
- 2005-07-25 RS RS20110539A patent/RS52057B2/sr unknown
- 2005-07-25 AT AT05763065T patent/ATE532503T1/de active
- 2005-07-25 CN CN2010101990195A patent/CN101884626A/zh active Pending
- 2005-07-25 EP EP05763065.9A patent/EP1789021B2/en not_active Expired - Lifetime
- 2005-07-25 MX MX2007001706A patent/MX2007001706A/es active IP Right Grant
- 2005-08-12 TW TW099130762A patent/TWI347850B/zh not_active IP Right Cessation
- 2005-08-12 US US11/202,715 patent/US20060051417A1/en not_active Abandoned
- 2005-08-12 TW TW094127584A patent/TWI347199B/zh not_active IP Right Cessation
- 2005-08-12 AR ARP050103377A patent/AR050602A1/es not_active Application Discontinuation
- 2005-08-12 US US11/202,713 patent/US7695734B2/en active Active
-
2007
- 2007-01-03 ZA ZA200700085A patent/ZA200700085B/en unknown
- 2007-01-03 ZA ZA200700086A patent/ZA200700086B/en unknown
- 2007-02-07 NO NO20070733A patent/NO342453B1/no unknown
- 2007-02-08 NO NO20070719A patent/NO20070719L/no not_active Application Discontinuation
- 2007-02-12 IL IL181283A patent/IL181283A/en not_active IP Right Cessation
- 2007-02-12 IL IL181282A patent/IL181282A/en active IP Right Grant
- 2007-02-13 EC EC2007007242A patent/ECSP077242A/es unknown
- 2007-02-13 EC EC2007007241A patent/ECSP077241A/es unknown
-
2009
- 2009-02-02 JP JP2009021694A patent/JP2009102409A/ja active Pending
- 2009-03-25 US US12/410,855 patent/US20090182024A1/en not_active Abandoned
- 2009-07-22 US US12/507,256 patent/US8377977B2/en active Active
-
2011
- 2011-01-26 JP JP2011014292A patent/JP2011084577A/ja not_active Withdrawn
- 2011-02-03 CY CY20111100128T patent/CY1111713T1/el unknown
- 2011-03-22 JP JP2011062986A patent/JP2011126916A/ja not_active Withdrawn
- 2011-11-09 AU AU2011250676A patent/AU2011250676A1/en not_active Abandoned
-
2012
- 2012-01-24 CY CY20121100080T patent/CY1112268T1/el unknown
- 2012-06-12 IL IL220313A patent/IL220313A0/en unknown
- 2012-10-09 US US13/647,865 patent/US20130274300A1/en not_active Abandoned
-
2014
- 2014-07-24 US US14/340,022 patent/US20140335175A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01442B (me) | Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjena | |
| JP2008509192A5 (me) | ||
| US6531153B2 (en) | Composition with sustained release of levodopa and carbidopa | |
| CN1241946A (zh) | 快速崩解性医药组合物 | |
| AU784128B2 (en) | Ibuprofen containing active agent preparation | |
| RU2669351C1 (ru) | Покрытая пленкой таблетка, содержащая холина альфосцерат, и способ ее изготовления | |
| ES2768349T3 (es) | Preparación farmacéutica que comprende un derivado de fenilalanina | |
| WO2005013964A1 (ja) | ナテグリニド含有製剤 | |
| CN101219120B (zh) | 替米沙坦分散片及其制备方法 | |
| RU2009103658A (ru) | Фармацевтические композиции мемантина | |
| US20070190020A1 (en) | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture | |
| Takasaki et al. | The importance of binder moisture content in Metformin HCL high-dose formulations prepared by moist aqueous granulation (MAG) | |
| WO2002087549A1 (fr) | Comprimes a liberation prolongee du type a unites multiples | |
| CN101401816B (zh) | 一种聚卡波非钙颗粒的制备方法 | |
| JPH08310969A (ja) | 固形薬品組成物及びその製造方法 | |
| Preetha et al. | Comparative evaluation of mode of incorporation of superdisintegrants on dissolution of model drugs from wet granulated tablets | |
| JP2002012540A (ja) | 水易溶性薬物含有錠剤 | |
| JPWO2004006945A1 (ja) | 漢方エキス含有錠剤組成物およびその製造方法 | |
| CN102423482B (zh) | 复方氨氯地平赖诺普利片的制备方法 | |
| CN112057427B (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
| WO2020122244A1 (ja) | 錠剤及びその製造方法 | |
| CN111249246A (zh) | 一种左乙拉西坦缓释片剂及其制备方法 | |
| CN111601590A (zh) | 一种海泽麦布片剂及其制备方法 | |
| CN102578449A (zh) | 一种含氨基葡萄糖的三层泡腾片的制备工艺 | |
| Emshanova | Methodological approaches to the selection of excipients for preparation of tablets by direct pressing |